Selecting new classes and MOAs for ADC payload discovery
09 Feb 2027
ADC Linker Design & Conjugation Technologies
- How is the ADC space continuing to grow, and why does it remain heavily focused on similar payload types?
- Which different payloads may have greater potential for patients who do not respond to established TOPOi and tubulin inhibitor ADCs?
- What new approaches are in preclinical and early clinical development, including new cytotoxics and inhibitors, degrader-antibody conjugates, and radionuclides?
- Why has consensus not yet emerged on the key areas of focus and the best ways to identify promising new candidates?
Industry Expert
